The rational application of mammalian target of rapamycin inhibitor in organ transplantation
10.3760/cma.j.cn421203-20240716-00166
- VernacularTitle:哺乳动物雷帕霉素靶蛋白抑制剂在实体器官移植中的合理应用
- Author:
Ning LI
1
;
Mingjun WANG
1
;
Xiaohong GUO
1
Author Information
1. 山西省第二人民医院肾移植中心，太原 030012
- Publication Type:Journal Article
- Keywords:
Organ transplantation;
Mammalian target of rapamycin inhibitor;
Application;
Side effect
- From:
Chinese Journal of Organ Transplantation
2025;46(8):575-580
- CountryChina
- Language:Chinese
-
Abstract:
Mammalian target of rapamycin inhibitor (mTORi) not only exert strong immunosuppressive effects, but also possess multiple potential benefits, including antiviral, antitumor, antifibrotic, and anti-aging properties. Their long-term efficacy in the field of organ transplantation has been well established, and they have been widely applied in clinical practice. However, the adverse effects of mTORi-such as impaired wound healing, oral ulcers, anemia, proteinuria, hyperglycemia, dyslipidemia, pneumonia, lymphedema, and angioedema-remain a challenge in clinical settings. In immunosuppressive regimens for organ transplantation, mTORi are used in diverse combination therapies and exhibit considerable inter-individual variability. This article briefly reviews recent research progress on mTORi in solid organ transplantation (SOT) and discusses strategies for their rational application, aiming to provide useful insights for clinical practice.
